The goal of the study is to evaluate the effectiveness and side effects of a potentially new treatment option for volunteers with moderate to severe dry eye disease.
Approximately 670 volunteers with moderate to severe dry eye disease will be recruited across the United States.
The study will last about 8 weeks and includes up to 5 in-clinic visits. Eligible participants may receive up to $1,700 in compensation for completing 5 study visits. Reimbursement for transportation by car service (i.e., Uber, Lyft, Taxi) to and from the study visits may be provided at no cost if needed.
To determine your eligibility, please complete the form below. Our patient engagement team will contact you to ask more questions and provide more information about the study.
You may qualify to participate if you:
Are 18 years or older
Have a diagnosis of moderate to severe Dry Eye Disease (DED) for at least 6 months
Have used or desired to use eye drops for dry eye symptoms in the last 6 months
Have NOT had LASIK surgery in the last 12 months or any other eye surgery in the last 3 months
If you qualify for this study, here is what you can expect:
During these visits, you will go through a series of assessments, including:
In addition, there are other assessments that the study team will discuss with you in detail during your screening visit.
We are currently conducting this study nationwide, with new locations coming soon. Take a look at our current locations below to find out if we have a study location near you.
The study will last approximately 8 weeks and involves up to 5 in–person visits.
Taking part in any clinical study is entirely voluntary. Your decision whether or not to participate will not affect the medical care you currently receive or may receive in the future. If you qualify and opt to join the study, you have the freedom to withdraw at any time and for any reason.
Your personal and medical information is completely protected before, during and after the clinical trial process through the HIPAA (Health Insurance Portability and Accountability Act) Privacy Rule. You will also be informed of who has access to your personal information.
Telios Pharma, Inc. is responsible for conducting this clinical study.
Key Inclusion Criteria
Key Exclusion Criteria
Sign up for email alerts when new trials and locations are added for a medical condition.
